SOUTH SAN FRANCISCO — Long before "unicorn" and "disruption" became Silicon Valley's favorite words, a scrappier industrial city 10 miles south of downtown San Francisco was quietly becoming the birthplace of a completely different kind of tech. The signs on Highway 101 still call it "The Industrial City." The biotech industry that grew up here over the past five decades has another name for it: ground zero.
Related: HOW SAN FRANCISCO'S SOURDOUGH BECAME A CITY'S EDIBLE IDENTITY · UNDER THE BRIDGE, A MURAL MOVEMENT: HOW CHICANO PARK BECAME A NATIONAL LANDMARK
The origin story runs through a partnership between a UC San Francisco biochemist named Herbert Boyer and a young venture capitalist named Robert Swanson. Boyer, working with Stanford's Stanley Cohen, had helped pioneer recombinant DNA technology in the early 1970s, a method for splicing genes from one organism into another. Swanson, as industry lore has it, cold-called Boyer and asked for a meeting. What came out of that conversation was Genentech, founded in 1976 and widely cited as the first company built specifically to commercialize genetic engineering.
Genentech's early work centered on getting bacteria to produce human proteins, which was a radical idea at the time. The company's engineered human insulin, developed with a major pharmaceutical partner, became one of the first genetically engineered drugs to hit the market in the early 1980s. It replaced insulin derived from pig and cattle pancreases, a supply chain that had defined diabetes treatment for decades. The success handed biotech a template it still follows: find a naturally occurring protein with therapeutic value, then use engineered cells to manufacture it at scale.
Genentech eventually moved its headquarters to South San Francisco, and its growth pulled other biotech firms, academic spinoffs, and pharmaceutical research units into the same stretch of the Peninsula. Cheap industrial real estate, proximity to UCSF and Stanford, and a ready supply of molecular biologists made the area attractive in ways that had nothing to do with software. The city eventually leaned all the way into it. Municipal welcome signs now describe South San Francisco as the birthplace of biotechnology, a claim few in the industry bother to argue.
The parallels with California's software story are real, but so are the gaps. Both industries drew on research out of California's public and private universities. Both needed venture capital willing to fund years of work before any product reached a customer. But biotech runs on a completely different clock. A software startup can ship in months and iterate on user feedback. A drug candidate can spend a decade or longer in development and clinical trials before regulators weigh in, and most candidates never make it that far. That timeline shaped everything about the culture that grew up around Genentech: patient capital, specialized lab space, and a tolerance for scientific dead ends that Silicon Valley's software world rarely has to accommodate.
The geography reflects that difference. Software companies scattered themselves across garages, strip malls, and eventually gleaming campuses throughout Santa Clara County. Biotech needed wet labs, fume hoods, cold storage, and biosafety infrastructure, which pushed the industry toward purpose-built clusters. South San Francisco's biotech district filled in with low-rise research buildings rather than glass towers. The skyline looks more like a pharmaceutical campus than a tech park, because that is largely what it is.
The city's success helped seed biotech hubs elsewhere in the state, including a cluster in San Diego built around genomics research and academic ties to UC San Diego and the Salk Institute. Together, the two regions turned California into the dominant state for biotechnology employment and venture investment in the U.S., according to industry trade groups. That dominance has held even as the software side of the state's tech economy has cycled through multiple boom-and-bust periods, from the dot-com crash of 2000 to the more recent contraction in venture funding for consumer internet startups.
Biotech has had its own reckonings. Drug pricing controversies, patent disputes, and periodic waves of clinical trial failures have all tested the industry's economics. Genentech itself was acquired by Swiss pharmaceutical giant Roche in a deal finalized in 2009, ending its run as an independent public company, though it continues to operate its South San Francisco research campus under the Roche umbrella. The broader cluster has kept expanding regardless, with newer entrants working on gene therapy, immunotherapy, and messenger RNA technology. That last one got a very public moment during COVID-19 vaccine development.
What has not changed is the basic case for why the industry landed in California in the first place. The state's public university system produced the research and the researchers. Its early venture capital networks, already forming around what would become Silicon Valley, were willing to bet on science that most investors elsewhere considered too speculative or too slow.